Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATI-450 in moderate-to-severe COVID-19
NCT04481685Phase 2Completed
- Sponsor
- University of Kansas Medical Center
- Start
- Jul 2020
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zunsemetinib in coronavirus disease 2019 (COVID-19), sponsored by University of Kansas Medical Center. Started Jul 2020; status: completed.
02
Drugs
zunsemetinib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04481685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04481685.